Floatz logo

Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)

Esophageal Varices

General Hospital of Shenyang Military Regionprotein_peptidePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Esophageal Varices cohort.

Asset / SponsorPhaseRating
Apsolol
West China Hospital
Phase 4BBB
CARVEDILOL
West China Hospital
Phase 4BBB
L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R*,R*))-
Shanghai Zhongshan Hospital
Phase 4BB
Apixaban
Asian Institute Of Medical Sciences
Phase 4BB
Ophtamolol
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB

View all 14 →

Same molecule, other indications

Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) is also rated in:

hepatorenal syndromeActive
A
Indicative · Phase 4
84 / 100
View asset →
cirrhosis of liverActive
BBB
Indicative · Phase 4
77 / 100
View asset →
upper digestive tract disorderDormant
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →